Profile | DEVELOPER

Logo	Name	Type	Year of Establishment	Industry Tag
	Biostate AI	Startup	2023	Medical
Hi we’re Biostate AI! Biostate AI is a biotech startup (founded 2023) operating in Houston, Palo Alto, Bangalore, and Shanghai that combines high-throughput, cost-effective RNA sequencing (via proprietary BIRT/PERD tech) with generative AI to predict disease progression and treatment response from transcriptomic data .
	HAYA Therapeutics	Startup	2019	Medical
Hi we’re HAYA Therapeutics! HAYA Therapeutics is a Swiss?U.S. biotech pioneering precision RNA-guided therapeutics by targeting long non?coding RNAs (lncRNAs) from the ""dark genome"" to reprogram disease-driving cell states across chronic, cardiovascular, metabolic, fibrotic, and oncologic conditions . In May 2025, HAYA closed a $65?M Series?A led by Sofinnova and Earlybird to advance its lead lncRNA candidate HTX?001 into clinical trials for heart failure, while expanding its pipeline and establishing a major collaboration with Lilly to explore metabolic disease targets
	Danaher Corporation	Industry Player	1969	Synthetic Biology
Hi we’re Danaher Corporation! Danaher Corporation is a global science and technology conglomerate whose Life Sciences arm—including Cytiva, Pall, and Integrated DNA Technologies—is a cornerstone in advancing synthetic biology workflows from design to biomanufacturing . Through strategic acquisitions like IDT for custom oligonucleotides and partnerships with genomic and CRISPR innovators, Danaher empowers synthetic biology researchers and biopharma companies with essential tools for DNA/RNA synthesis, genome editing, and scalable biologics production
	Almac Discovery	Industry Player	2008	Medical
Hi we’re Almac Discovery! Almac Discovery is a UK?based, research-led drug discovery subsidiary of the Almac Group, advancing innovative therapeutics from discovery through preclinical stages with capabilities in protein engineering, bioinformatics, medicinal chemistry, and synthetic biology support services?. Its recent global licensing partnership with Formosa Pharmaceuticals for ALM?401—a first-in-class EGFR × ROR1 bispecific ADC—highlights Almac’s strength in protein homeostasis and ADC/PDC platforms for oncology development?.
	Formosa Pharmaceuticals	Industry Player	2010	Medical
Hi we’re Formosa Pharmaceuticals! Formosa Pharmaceuticals is a Taipei?based clinical-stage biopharma company leveraging its proprietary APNT® nanoparticle formulation platform to enhance delivery and bioavailability of ophthalmology, oncology, and anti-infective agents . Its flagship product, APP13007 (clobetasol propionate ophthalmic nanosuspension), received FDA approval in March 2024 and is being commercialized globally through licensing agreements for post-operative inflammation and pain
	Rznomics	Startup	2017	Medical
Hi we’re Rznomics! Rznomics is a South Korea–based clinical-stage biotech pioneering RNA editing via its proprietary trans-splicing ribozyme (TSR) and circular RNA platforms for precision therapeutics in oncology, rare genetic, and degenerative diseases . They’re advancing lead candidates like RZ-001 (for liver cancer and glioblastoma, which has FDA Fast Track & EAP status) and RZ-004 (for retinitis pigmentosa), and have secured a global licensing deal worth up to $1.3?billion with Eli Lilly for treating inherited hearing loss
	Orionis Biosciences	Industry Player	2015	Medical
Hi we’re Orionis Biosciences! Orionis Biosciences is a clinical-stage biotech pioneering induced?proximity therapeutic platforms—to engineer molecular glues, conditioned cytokines (A?Kines™), and cell engagers—targeting challenging oncology proteins and immune pathways . Recently, it secured a second strategic collaboration with Genentech in May?2025—receiving $105?million upfront and eligibility for over $2?billion in milestones—to discover and develop small-molecule monovalent “glue” medicines for hard-to-drug cancer targets
	AccurEdit Therapeutics	Startup	2021	Medical
Hi we’re AccurEdit Therapeutics! AccurEdit Therapeutics is a Suzhou and Massachusetts–based clinical-stage biotech pioneering systemic in vivo gene editing using a proprietary CRISPR/Cas base editor and LNP delivery platform—achieving landmark FDA RMAT designation and first-in-human trials in both China and the U.S. for its lead candidates targeting ATTR amyloidosis (ART001) and familial hypercholesterolemia (ART002), with sustained >90% protein reduction and strong safety profiles